2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Breast Neoplasms
102
Neoplasm Metastasis
26
Neoplasms
15
Brain Neoplasms
13
Prostatic Neoplasms
10
Endometrial Neoplasms
10
Carcinoma, Non-Small-Cell Lung
10
Ovarian Neoplasms
7
Glioblastoma
7
Glioma
6
Triple Negative Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Head and Neck Neoplasms
5
Colorectal Neoplasms
5
Breast Diseases
5
Sarcoma
4
Recurrence
4
Pancreatic Neoplasms
4
Lymphoma, Non-Hodgkin
4
Sarcoma, Ewing
3
Osteosarcoma
3
Neoplasms by Site
3
Multiple Myeloma
3
Meningioma
3
Melanoma
3
Liposarcoma
3
Carcinoma, Renal Cell
3
Unilateral Breast Neoplasms
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Interventions
Cisplatin
116
Radiotherapy
84
Paclitaxel
77
Fluorouracil
62
Carboplatin
41
Drug Therapy
38
pembrolizumab
33
Irinotecan
33
tislelizumab
27
Docetaxel
26
Neoadjuvant Therapy
24
Oxaliplatin
23
toripalimab
22
sintilimab
19
camrelizumab
19
Radiation
19
Esophagectomy
18
Capecitabine
17
130-nm albumin-bound paclitaxel
17
Surgical Procedures, Operative
16
Nivolumab
16
Leucovorin
15
Cetuximab
14
TP protocol
12
S 1 (combination)
12
Radiotherapy, Intensity-Modulated
12
Albumin-Bound Paclitaxel
12
nimotuzumab
11
apatinib
10
Immune Checkpoint Inhibitors
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Squamous Cell Carcinoma
×
abemaciclib
×
Clear all
NCT03339843
2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2
Completed
85 enrolled